Fresenius Biotech GmbH is a company of the Fresenius health care group, focused on the development and marketing of biopharmaceuticals in the fields of oncology and immunology/transplantation medicine.
The main business activities of Fresenius Biotech are:
- Immunosuppression in organ transplantation
- Development of trifunctional antibodies for cancer treatment
Fresenius Biotech is manufacturing and commercializing an immunosuppressive agent, a polyclonal antibody that is used in organ transplantation. This medicinal product has been proven to be effective in suppressing the rejection of organs by the immune system. Currently, the efficacy and safety of this immunosuppressant are being assessed in clinical trials for bone marrow transplantation and stem cell transplantation.
Development of trifunctional antibodies for cancer treatment
This innovative therapy with trifunctional antibodies activates the immune system to destroy tumor cells. Currently, clinical studies are investigating the antibodies for use against various tumors. Possible therapeutic options for future applications of the antibodies could be an adjuvant setting (after surgical resection of a tumor) or as additional immune therapy after previous chemo- or radiation therapy. Fresenius Biotech has successfully completed several clinical studies. The European Commission has approved the trifunctional antibody Removab (catumaxomab) for the treatment of malignant ascites. Trifunctional antibodies are a development of our partner TRION Pharma.
Clinical Studies with Trifunctional Antibodies (PDF, 54 KB)
Company Profile (PDF, 318 KB)
General Terms and Conditions of Sales (PDF, 51 KB)
Glossary (PDF, 116 KB)